Literature DB >> 7474363

Nicorandil suppresses a hump on the monophasic action potential and torsade de pointes in a patient with idiopathic long QT syndrome.

M Chinushi1, Y Aizawa, H Furushima, H Inuzuka, K Ojima, A Shibata.   

Abstract

The patient was a 71-year-old female with Torsade de Pointes (TdP) associated with idiopathic long QT syndrome. TdP and polymorphic nonsustained VT were frequently observed at bedside and an electrophysiologic study was performed. The QT (and QTU) interval was abnormally prolonged, and alteration of the QT interval was also recorded on the electrocardiogram. Monophasic action potential (MAP) from the right ventricle showed a hump on the falling limb of the MAP following a long RR interval of more than 1.0 sec. Intravenous administration of nicorandil (2 mg) resulted in disappearance of the hump, and ventricular arrhythmia was no longer observed. The QT interval at a PP interval of 720 msec was slightly shortened. She was treated with a DDD-pacemaker and given nicorandil. No recurrence of TdP was observed during the follow-up period of 8 months. This drug might be effective in patients with idiopathic long QT syndrome.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7474363     DOI: 10.1536/ihj.36.477

Source DB:  PubMed          Journal:  Jpn Heart J        ISSN: 0021-4868


  6 in total

Review 1.  Drug-induced QT interval shortening: potential harbinger of proarrhythmia and regulatory perspectives.

Authors:  Rashmi R Shah
Journal:  Br J Pharmacol       Date:  2009-06-25       Impact factor: 8.739

2.  Nicorandil abolished repolarisation alternans in a patient with idiopathic long QT syndrome.

Authors:  Y Fujimoto; H Morita; K K Fukushima; T Ohe
Journal:  Heart       Date:  1999-11       Impact factor: 5.994

Review 3.  Prevention of ventricular arrhythmias in the congenital long QT syndrome.

Authors:  S Viskin; R Fish
Journal:  Curr Cardiol Rep       Date:  2000-11       Impact factor: 2.931

4.  Clinical suppression of bradycardia dependent premature ventricular contractions by the potassium channel opener nicorandil.

Authors:  N Takahashi; M Ito; T Saikawa; M Arita; T Fujino; H Kagiyama; T Fukumoto; T Sakata
Journal:  Heart       Date:  1998-01       Impact factor: 5.994

Review 5.  Cardiac repolarisation and drug regulation: assessing cardiac safety 10 years after the CPMP guidance.

Authors:  Rashmi R Shah
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

6.  Effects of potassium channel openers in the isolated perfused hypokalaemic murine heart.

Authors:  M J Killeen; G Thomas; S-P Olesen; J Demnitz; K S Stokoe; A A Grace; C L-H Huang
Journal:  Acta Physiol (Oxf)       Date:  2007-11-14       Impact factor: 6.311

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.